<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ARIPIPRAZOLE</span><br/>(a-rip'-i-pra-zole)<br/><span class="topboxtradename">Abilify<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">antipsychotic</span>; <span class="classification">atypical</span><br/><b>Prototype: </b>Clozapine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 15 mg, 20 mg, 30 mg tablets; 1 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Exhibits high affinity for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2C</sub> and 5-HT<sub>7</sub>, alpha-1 adrenergic and histamine H<sub>1</sub> receptors, and moderate affinity for the serotonin reuptake site. Functions as a partial agonist at the dopamine D<sub>2</sub> and the serotonin 5-H<sub>1A</sub> receptors, and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The mechanism of action is unknown. Efficacy of aripiprazole may be mediated through a combination of partial agonist activity
         at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors and antagonist activity at 5-HT<sub>2A</sub> receptors. Actions at other receptors may explain some other clinical effects of aripiprazole (e.g., orthostatic hypotension).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of schizophrenia, bipolar mania, maintenance in bipolar 1 disorder.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Depression with psychotic features.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to aripiprazole; lactation; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of seizures or conditions that lower seizure threshold (e.g., Alzheimer's dementia); suicidal ideation; brain tumor;
         dementia; diabetes mellitus; patients with known cardiovascular disease (history of MI or ischemic heart disease, heart failure,
         or conduction abnormalities), cerebrovascular disease, or conditions that predispose to hypotension (dehydration, hypovolemia,
         and treatment with antihypertensive medications); dysphagia; ethanol intoxication; hyperglycemia, hypothermia; obesity, elderly,
         children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Schizophrenia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1015 mg once daily, may increase at 2-wk intervals to max of 30 mg/d if needed<br/><br/><span class="indicationtitle">Bipolar Mania</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg once daily, may reduce to 15 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that dose should be reduced by 50% with concurrent treatment with ketoconazole, quinidine, fluoxetine, or paroxetine.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Headache,</span> asthenia, fever, flu-like symptoms, peripheral edema, chest pain, neck pain, neck rigidity. <span class="typehead">CNS:</span>
<span class="speceff-common">Anxiety, insomnia, lightheadedness, somnolence, akathisia</span>, tremor, extrapyramidal symptoms, depression, nervousness, increased salivation, hostility, suicidal thought, manic reaction,
      abnormal gait, confusion, cogwheel rigidity. <span class="typehead">CV:</span> Hypertension, tachycardia, hypotension, bradycardia. <span class="speceff-life">Risk of stroke in elderly with dementia-related psychosis.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, constipation,</span> anorexia. <span class="typehead">Hematologic:</span> Ecchymosis, anemia. <span class="typehead">Metabolic:</span> Weight gain, weight loss, hyperglycemia, diabetes mellitus, increased creatine kinase. <span class="typehead">Musculoskeletal:</span> Muscle cramp. <span class="typehead">Respiratory:</span> Rhinitis, cough. <span class="typehead">Skin:</span> Rash. <span class="typehead">Special Senses:</span> Blurred vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Carbamazepine</b> will decrease aripiprazole levels (may need to double aripiprazole dose); <b>ketoconazole,</b>
<b>quinidine,</b>
<b>fluoxetine,</b>
<b>paroxetine</b> may increase aripiprazole levels (reduce dose by ½); may enhance effects of <span class="classification">antihypertensive agents</span>. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease aripiprazole levels.  <span class="typehead">Food:</span> High fat meals may delay time to peak plasma levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed, 87% bioavailable. <span class="typehead">Peak:</span> 35 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4 and 2D6. Major metabolite, dehydroaripiprazole has some activity. <span class="typehead"> Elimination:</span> 55% excreted in feces, 25% in urine. <span class="typehead">Half-Life:</span> 75 h (94 h for metabolite). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Monitor cardiovascular status. Assess for and report orthostatic hypotension. Take BP supine then in sitting position. Report
            systolic drop of &gt;1520 mm Hg. Patients at increased risk are those who are dehydrated, hypovolemic, or receiving concurrent
            antihypertensive therapy.
         </li>
<li>Monitor body temperature in situations likely to elevate core temperature (e.g., exercising strenuously, exposure to extreme
            heat, receiving drugs with anticholinergic activity, or being subject to dehydration).
         </li>
<li>Monitor for and report signs of tardive dyskinesia.</li>
<li>Monitor for and immediately report S&amp;S of neuroleptic malignant syndrome (NMS) that include: hyperpyrexia, muscle rigidity,
            altered mental status, irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia. Withhold drug
            if NMS is suspected.
         </li>
<li>Lab tests: Monitor periodically Hct &amp; Hgb. Monitor periodically blood glucose. Monitor for elevated CPK and myoglobinuria
            if NMS is suspected.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Do not drive or engage in other potentially hazardous activities until reaction to drug is known.</li>
<li>Avoid situations where you are likely to become overheated or dehydrated.</li>
<li>Notify physician if you become pregnant or intend to become pregnant while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>